{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T02:43:55Z","timestamp":1795229035773,"version":"4.10.3"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To report early safety and efficacy of Descemet stripping only (DSO) supplemented with ripasudil.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A pre-post clinical trial with a historical control group for time to heal and cell count parameters. The study received ethics approval and was conducted with oversight of a data safety monitoring board. All enrolled patients had a superior endothelial cell count of &gt;1000 cells\/mm<jats:sup>2<\/jats:sup> and were symptomatic from the presence of central guttata degrading vision and\/or producing glare. DSO was carried out with a peeling technique and not combined with any other intervention. Ripasudil 0.4% was applied topically from day 1 postoperatively at a dose of 6 times\/d until corneal clearance. Cases with relapse of edema were permitted to restart on ripasudil at a reduced dose of 2 drops\/d for a further 2 weeks. Stopping rules with progression to a corneal graft were established. Baseline ocular and systemic investigations were carried out and repeated at varying intervals to monitor for local and systemic adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty-three eyes of 23 patients met the inclusion criteria and underwent DSO. Twenty-two of 23 eyes achieved corneal clearance at a mean time of 4.1 weeks. In all patients achieving clearance, improvement in vision was recorded. Improvement in mean uncorrected visual acuity was 0.20 Logarithm of the minimum angle of resolution (LogMar), and improvement in mean best spectacle corrected visual acuity was 0.156 LogMar. One patient failed to clear and underwent Descemet membrane endothelial keratoplasty at week 12. Twenty-one of 22 patients achieving corneal clearance expressed satisfaction with the procedure. The commonest systemic side effect of topical ripasudil was gastrointestinal upset (24%), and the commonest local side effect was ocular irritation (43%). No patient experienced a serious adverse event in the course of the trial. Thirty-nine percent of patients experienced a relapse of edema on ceasing ripasudil, with clearance again on recommencing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This trial of DSO supplemented with ripasudil included local and systemic safety analysis. We judge that this treatment option is emerging as a reliable intervention for select patients with Fuchs' Endothelial Corneal Dystrophy (FECD) with an acceptable safety profile. The observation of relapse edema is strong evidence of a drug effect. The longevity of these results remains unknown.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000002437","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T01:00:11Z","timestamp":1596330011000},"page":"320-326","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":77,"title":["Descemet Stripping Only Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study"],"prefix":"10.1097","volume":"40","author":[{"given":"Gregory","family":"Moloney","sequence":"first","affiliation":[{"name":"Discipline of Ophthalmology, Sydney Medical School, The University of Sydney, Sydney, Australia;"},{"name":"Sydney Eye Hospital, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Garcerant Congote","sequence":"additional","affiliation":[{"name":"Sydney Eye Hospital, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Hirnschall","sequence":"additional","affiliation":[{"name":"VIROS\u2014Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna, Austria; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Arsiwalla","sequence":"additional","affiliation":[{"name":"Sydney Eye Hospital, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Luiza Mylla Boso","sequence":"additional","affiliation":[{"name":"Sydney Eye Hospital, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Toalster","sequence":"additional","affiliation":[{"name":"Sydney Eye Hospital, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"D'Souza","sequence":"additional","affiliation":[{"name":"Discipline of Ophthalmology, Sydney Medical School, The University of Sydney, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj N.","family":"Devasahayam","sequence":"additional","affiliation":[{"name":"Discipline of Ophthalmology, Sydney Medical School, The University of Sydney, Sydney, Australia;"},{"name":"Sydney Eye Hospital, Sydney, Australia;"},{"name":"Lions NSW Eye Bank, OTDS (Organ & Tissue Donation Service), Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"R1-20250728","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/ICO.0000000000001883","article-title":"Use of topical rho kinase inhibitors in the treatment of fuchs dystrophy after Descemet stripping only","volume":"38","author":"Macsai","year":"2019","journal-title":"Cornea"},{"key":"R2-20250728","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/ICO.0000000000000915","article-title":"Treatment of Fuchs endothelial dystrophy by Descemet stripping without endothelial keratoplasty","volume":"35","author":"Borkar","year":"2016","journal-title":"Cornea"},{"key":"R3-20250728","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/ICO.0000000000001209","article-title":"Descemetorhexis without grafting for Fuchs endothelial dystrophy-supplementation with topical ripasudil","volume":"36","author":"Moloney","year":"2017","journal-title":"Cornea"},{"key":"R4-20250728","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/ICO.0000000000001202","article-title":"Descemetorhexis without graft placement for the treatment of Fuchs endothelial dystrophy: preliminary results and review of the literature","volume":"36","author":"Iovieno","year":"2017","journal-title":"Cornea"},{"key":"R5-20250728","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2012.08.037","article-title":"Spontaneous corneal clearing after Descemet's stripping","volume":"120","author":"Bleyen","year":"2013","journal-title":"Ophthalmology"},{"key":"R6-20250728","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/ICU.0000000000000579","article-title":"Descemet's stripping without endothelial keratoplasty","volume":"30","author":"Garcerant","year":"2019","journal-title":"Curr Opin Ophthalmol"},{"key":"R7-20250728","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/fca.11.51","article-title":"Rho kinase as a therapeutic target in cardiovascular disease","volume":"7","author":"Surma","year":"2011","journal-title":"Future Cardiol"},{"key":"R8-20250728","first-page":"276","article-title":"The function of rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease similarities and differences of ROCK1 and ROCK2 in structure and expression","volume":"6","author":"Cuello","year":"2015","journal-title":"Front Pharmacol"},{"key":"R9-20250728","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1016\/j.bmcl.2014.09.002","article-title":"Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension","volume":"24","author":"Shaw","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"R10-20250728","doi-asserted-by":"crossref","first-page":"e0136802","DOI":"10.1371\/journal.pone.0136802","article-title":"Morphological changes of human corneal endothelial cells after rho-associated kinase inhibitor eye drop (ripasudil) administration: A Prospective Open-Label Clinical Study","volume":"10","author":"Nakagawa","year":"2015","journal-title":"PLoS One"},{"key":"R11-20250728","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/ICO.0b013e318285475d","article-title":"Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy","volume":"32","author":"Koizumi","year":"2013","journal-title":"Cornea"},{"key":"R12-20250728","first-page":"2439","article-title":"The ROCK inhibitor eye drop accelerates corneal endothelium wound healing","volume":"54","author":"Okumura","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R13-20250728","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/ICO.0b013e3182281ee1","article-title":"The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction","volume":"30","author":"Okumura","year":"2011","journal-title":"Cornea"},{"key":"R14-20250728","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","article-title":"Ripasudil: First global approval","volume":"74","author":"Garnock-Jones","year":"2014","journal-title":"Drugs"},{"key":"R15-20250728","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5694\/j.1326-5377.2008.tb02077.x","article-title":"Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications?","volume":"189","author":"Goldberg","year":"2008","journal-title":"Med J Aust"},{"key":"R16-20250728","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/13543776.2017.1272579","article-title":"Rho kinase inhibitors: a patent review (2014\u20132016)","volume":"27","author":"Defert","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"R17-20250728","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00005344-200211000-00013","article-title":"Anti-anginal effect of fasudil, a rho-kinase inhibitor, in patients with stable effort angina: a multicenter study","volume":"40","author":"Shimokawa","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"R18-20250728","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0165-6147(00)01596-0","article-title":"Rho-rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells","volume":"22","author":"Fukata","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"R19-20250728","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1469-7793.2000.t01-2-00177.x","article-title":"Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II","volume":"522","author":"Somlyo","year":"2000","journal-title":"J Physiol"},{"key":"R20-20250728","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00005344-200203000-00001","article-title":"Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases","volume":"39","author":"Shimokawa","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"R21-20250728","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1253\/jcj.64.1","article-title":"Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models","volume":"64","author":"Shimokawa","year":"2000","journal-title":"Jpn Circ J"},{"key":"R22-20250728","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/brainsci10010030","article-title":"Calcitonin gene-related peptide (CGRP) and cluster headache","volume":"10","author":"Belin","year":"2020","journal-title":"Brain Sci"},{"key":"R23-20250728","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICO.0000000000001427","article-title":"Predictive factors for corneal clearance after Descemetorhexis without endothelial keratoplasty","volume":"37","author":"Davies","year":"2018","journal-title":"Cornea"},{"key":"R24-20250728","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/clinids\/20.1.179","article-title":"Postulates for the evaluation of adverse reactions to drugs","volume":"20","author":"Hughes","year":"1995","journal-title":"Clin Infect Dis"},{"key":"R25-20250728","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1167\/iovs.17-22106","article-title":"Allogeneic Descemet's membrane transplantation enhances corneal endothelial monolayer formation and restores functional integrity following Descemet's stripping","volume":"58","author":"Bhogal","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R26-20250728","first-page":"2172","article-title":"Potential functional restoration of corneal endothelial cells in Fuchs corneal dystrophy by ROCK inhibitor (ripasudil)","volume":"60","author":"Kruse","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R27-20250728","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1167\/iovs.15-18300","article-title":"Predicative factors for corneal endothelial cell migration","volume":"57","author":"Soh","year":"2016","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R28-20250728","doi-asserted-by":"crossref","DOI":"10.1097\/ICO.0000000000002270","article-title":"5-year outcomes of Descemet stripping only in Fuchs dystrophy","author":"Artaechevarria Artieda","year":"2020","journal-title":"Cornea"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000002437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:09:27Z","timestamp":1753740567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000002437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000002437","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,30]]},"assertion":[{"value":"2020-03-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}